News & Videos - HORIZON THERAPEUTICS PUBLIC

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Horizon Therapeutics Public Limited Company (NasdaqGS: HZNP) to Amgen Inc. (NasdaqGS: AMGN). Under the terms of the proposed transaction, shareholders of Horizon will receive only $116.50 in cash for each share of Horizon that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or...

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Horizon Therapeutics Public Limited Company (NasdaqGS: HZNP) to Amgen Inc. (NasdaqGS: AMGN). Under the terms of the proposed transaction, shareholders of Horizon will receive only $116.50 in cash for each share of Horizon that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or...

SHAREHOLDER ALERT: Weiss Law Investigates Horizon Therapeutics Public Limited Company PR Newswire NEW YORK, Dec. 12, 2022 NEW YORK , Dec. 12, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Horizon Therapeutics Public Limited Company ("Horizon Therapeutics" or the "Company") (NASDAQ: HZNP) in connection with the proposed acquisition of the Company by Amgen Inc. (NASDAQ: AMGN). Under the terms of the...

-- New insights on the factors associated with tophi formation and total body disease burden of gout -- DUBLIN, Ireland, June 15, 2018 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP) presents multiple analyses of KRYSTEXXA® (pegloticase injection) clinical trial data underscoring the complex nature of chronic gout refractory to conventional therapies, also known as uncontrolled gout. The data are being presented in oral and poster sessions at the Annual European Congress of Rheumatology...

AMSTERDAM, The Netherlands, June 14, 2018 (GLOBE NEWSWIRE) -- Results from a new study presented in an oral presentation at the Annual European Congress of Rheumatology (EULAR 2018) show a dramatic 27 percent increase in emergency department (ED) visits between 2006 and 2014 for people living with gout in the United States. Horizon Pharma provided research support and funding for this study. "The dramatic increase in ED visits in the United States for patients with a primary diagnosis of gout...

-- People can join the campaign by texting the word “RARE” to 56512, which generates a donation to NORD -- DUBLIN, Ireland, June 04, 2018 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP) and the National Organization for Rare Disorders (NORD) today launched a new campaign recognizing rare disease innovation since the passing of the Orphan Drug Act in 1983. Beginning today in the main lobby of the 2018 Biotechnology Innovation Organization (BIO) International Convention in Boston,...

DUBLIN, Ireland, May 30, 2018 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP), today announced that the company will participate in the Goldman Sachs 39 th Annual Global Healthcare Conference on Tuesday, June 12, 2018 and will present at 10:40 a.m. PT. The presentation will be webcast live and may be accessed by visiting Horizon's website at http://ir.horizon-pharma.com . A replay of the webcast will be available for the event. About Horizon Pharma plc Horizon Pharma plc is focused on...

DUBLIN, Ireland, May 22, 2018 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP) today announced that it has been selected to FORTUNE and Great Place to Work’s 2018 “ Best Workplaces in Chicago ” list. Horizon ranked number four out of 25 other small and medium sized companies. “It’s a great honor that FORTUNE and Great Place to Work have again named Horizon Pharma as one of the top workplaces in Chicago,” said Timothy P. Walbert, chairman, president and chief executive officer....

DUBLIN, Ireland, May 22, 2018 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP) today marked Gout Awareness Day with the launch of Gout Revealed , which was created to spotlight real-life stories of people living with uncontrolled gout, a painful and debilitating inflammatory form of arthritis caused by too much uric acid in the blood that continues despite the use of oral medicines. The site features people sharing their experiences with the disease – from the impact of the pain and the...

-- First-Quarter 2018 Orphan and Rheumatology Net Sales of $172.2 Million Increased 11 Percent; Represented 77 Percent of Total Company Net Sales -- -- First-Quarter 2018 KRYSTEXXA Net Sales Growth of 48 Percent; Increasing Full-Year 2018 Net Sales Growth Guidance to More Than 65 Percent -- -- 50 Percent of Patients Now Enrolled in Teprotumumab Phase 3 Clinical Trial -- -- Establishing New Operating Structure Effective in Second-Quarter 2018, With Two Operating Segments: Orphan and Rheumatology;...

- Will Represent the Eighth and Ninth U.S. Patents to be Listed in the Orange Book for RAVICTI - DUBLIN, Ireland, May 08, 2018 (GLOBE NEWSWIRE) -- Horizon Pharma plc (Nasdaq:HZNP) today announced that it has received two Notices of Allowance from the United States Patent and Trademark Office for U.S. patent application numbers 15/457,643 and 15/687,132, both entitled "Methods of Therapeutic Monitoring of Nitrogen Scavenging Drugs” that cover Horizon's U.S. approved medicine RAVICTI (glycerol...

DUBLIN, IRELAND, May 04, 2018 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP) today announced that the compensation committee of its board of directors approved the grant on May 1, 2018 of inducement restricted stock units for an aggregate of 228,305 ordinary shares to 30 new employees. Certain of the restricted stock units vest over four years, with 25 percent of the shares vesting on each anniversary of the applicable vesting commencement date, and certain of the restricted stock units...

DUBLIN, Ireland, May 03, 2018 (GLOBE NEWSWIRE) -- Horizon Pharma plc (Nasdaq:HZNP) today announced that Sangita Iyer, director, financial planning and analysis, has been named a 2018 Healthcare Businesswomen's Association (HBA) Rising Star. Sangita will be honored today at the 29 th annual Woman of the Year event in New York. The HBA is the leading not-for-profit global organization committed to furthering the advancement and impact of women in healthcare worldwide. Sangita is being recognized...

- Company also awarded “Best Places to Work in Chicago” and “10 Best Places to Work for Women” by Crain’s Chicago Business - DUBLIN, Ireland, April 12, 2018 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP) today announced it has been selected as the number one place to work by Great Place to Work® and FORTUNE Magazine on its " Best Workplaces in Health Care & Biopharma " list. The company has also been awarded a 2018 “ Best Places to Work in Chicago ” designation by Crain’s...

DUBLIN, Ireland, April 09, 2018 (GLOBE NEWSWIRE) -- Horizon Pharma plc (Nasdaq:HZNP) announced today that its first-quarter financial results will be released on Wednesday, May 9, 2018. Following the announcement, Horizon's management will host a live webcast at 8 a.m. Eastern Time to review the Company's financial and operating results. The live webcast and replay may be accessed at http://ir.horizon-pharma.com . Please connect to the Company's website at least 15 minutes before the live...

DUBLIN, Ireland, April 04, 2018 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP) today announced that the compensation committee of its board of directors approved the grant on Apr. 1, 2018 of inducement restricted stock units for an aggregate of 55,395 ordinary shares to 21 new employees. Some of the restricted stock units vest over four years, with 1/4 of the shares vesting on each anniversary of the applicable vesting commencement date, and some of the restricted stock units vest over...

-- Fourth-Quarter 2017 Net Sales of $274.2 Million; Fourth-Quarter 2017 Net Loss of $46.4 Million; Adjusted EBITDA of $102.7 Million -- -- Fourth-Quarter 2017 Operating Cash Flow of $143.2 Million; Fourth-Quarter 2017 Non-GAAP Operating Cash Flow of $157.9 Million -- -- Full-Year 2017 Net Sales of $1.056 Billion; Full-Year 2017 Net Loss of $410.5 Million; Adjusted EBITDA of $389.7 Million -- -- Full-Year 2017 Operating Cash Flow of $280.2 Million; Full-Year 2017 Non-GAAP Operating Cash Flow of...

DUBLIN, Ireland, Feb. 27, 2018 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP) today announced that it has submitted a supplemental New Drug Application (sNDA) with the U.S. Food and Drug Administration (FDA) to expand the approved indication for RAVICTI® (glycerol phenylbutyrate) Oral Liquid to include infants younger than two months of age living with urea cycle disorders (UCDs). Currently, RAVICTI is indicated for use as a nitrogen-binding agent for chronic management of adult and...

WASHINGTON, Feb. 26, 2018 (GLOBE NEWSWIRE) -- Children’s National Health System and Horizon Pharma plc are pleased to announce the creation of the Horizon Pharma Clinical Care Endowment , the first clinical team endowment at the Children’s National Rare Disease Institute (CNRDI). The endowment is made possible by a generous $3 million commitment over six years from Horizon Pharma USA, Inc., a wholly owned subsidiary of Horizon Pharma plc. – a biopharmaceutical company dedicated to...

DUBLIN, Ireland, Feb. 26, 2018 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP) today announced that the company will present at the following conference in March: Cowen and Company 38 th Annual Health Care Conference Date: March 12, 2018 Presentation Time: 4:10 p.m. ET Location: Boston, Mass. The presentation will be webcast live and may be accessed by visiting Horizon's website at http://ir.horizon-pharma.com . A replay of the webcast will be available for the event. About Horizon Pharma...